License, Development and Commercialization Agreement between Sloan-Kettering Institute of Cancer Research and Actinium Pharmaceuticals, Inc.

This agreement is between the Sloan-Kettering Institute of Cancer Research and Actinium Pharmaceuticals, Inc. It grants Actinium the rights to use certain technologies developed by Sloan-Kettering for research, development, and commercialization purposes. The agreement outlines Actinium’s obligations to develop and market products based on these technologies, including payment of royalties and milestone fees. It also specifies conditions for amendments, such as the First Amendment dated August 7, 2006, and includes terms regarding intellectual property, confidentiality, and termination.